Targeting SLC7 A11 Ameliorates Ulcerative Colitis by Promoting Efferocytosis Through the ERK1/2 Pathway

Area of Science:

• Gastroenterology
• Immunology
• Molecular Biology

Background:

• Colitis, including ulcerative colitis, involves significant intestinal inflammation and barrier dysfunction.
• Solute carrier family 7 member 11 (SLC7A11) is implicated in cellular stress and inflammation.
• Understanding SLC7A11's role in colitis pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the therapeutic potential of targeting SLC7A11 in dextran sulfate sodium (DSS)-induced colitis.
• To elucidate the underlying mechanisms by which SLC7A11 influences intestinal inflammation and epithelial integrity.

Main Methods:

• Utilized wild-type and SLC7A11 knockout mice to model DSS-induced colitis in vivo.
• Analyzed human ulcerative colitis colon tissues to assess SLC7A11 expression.
• Employed Caco-2 cells and bone marrow-derived dendritic cells (BMDCs) for in vitro mechanistic studies.

Main Results:

• SLC7A11 expression was significantly higher in inflamed human colon tissues, particularly in dendritic cells.
• Inhibition of SLC7A11 ameliorated DSS-induced colitis symptoms and restored intestinal epithelial barrier integrity in vitro.
• SLC7A11 modulation enhanced dendritic cell efferocytosis and ERK1/2 phosphorylation.

Conclusions:

• Targeting SLC7A11 enhances dendritic cell efferocytosis, a key process in resolving inflammation.
• Preserving intestinal epithelial barrier function through SLC7A11 inhibition is a promising therapeutic strategy.
• SLC7A11 represents a potential therapeutic target for managing ulcerative colitis.